Multipurpose prevention technologies (MPTs) for prevention of HIV and pregnancy
Thursday, January 28, 2021
•
OA06
•
3:00 PM
>
4:00 PM
•
Multipurpose prevention technologies (MPTs) for prevention of HIV and pregnancy
•
Live channel 1
3:00 PM
•
OA06.01
•
Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy
See abstract
3:08 PM
•
OA06.02
•
Randomized, placebo-controlled trial of safety, pharmacokinetics, and pharmacodynamics of 90-day intravaginal rings (IVRs) releasing tenofovir (TFV) with and without levonorgestrel (LNG) among women in Western Kenya
See abstract
3:16 PM
•
OA06.03
•
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of a multipurpose prevention vaginal ring containing tenofovir and levonorgestrel
See abstract
3:24 PM
•
OA06.04
•
Heterosexual couples' preferences for dual-purpose prevention products for HIV and pregnancy prevention: the CUPID Study (MTN-045) in Uganda and Zimbabwe
See abstract
3:32 PM
•
OA06.05
•
A phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginally
See abstract
3:40 PM
•
OA06.06
•
Live Q&A
See abstract
|